Showing 21-30 of 338 results for "".
- Johnson & Johnson Completes Acquisition of Yellow Jersey Therapeuticshttps://practicaldermatology.com/news/Johnson-johnson-completes-acquisition-yellow-jersey-therapeutics/2467362/Johnson & Johnson has successfully completed the acquisition of Yellow Jersey, a demerged subsidiary of Numab Therapeutics, to secure the global rights to NM26, a novel, investigational first-in-class bispecific antibody being evaluated for the treatment of atopic dermatitis
- Johnson & Johnson Acquires Proteologix, Maker of Atopic Dermatitis Candidate, for $850 Millionhttps://practicaldermatology.com/news/johnson-johnson-acquires-proteologix-maker-atopic-dermatitis-candidate-850-million/2463090/Johnson & Johnson has entered into a definitive agreement to acquire biotech company Proteologix for $850 million in cash, with potential for an additional milestone payment. Proteologix’s portfolio includes PX128, a bispecific antibody targeting IL-13 plus TSLP, which is ready to ente
- Johnson & Johnson Announces Kenvue as the Name for New Consumer Health Companyhttps://practicaldermatology.com/news/johnson-johnson-announces-kenvue-as-the-name-for-new-consumer-health-company/2461363/Johnson & Johnson’s planned new consumer health company will be named...Kenvue. Kenvue (pronounced ken·view), is inspired by two powerful ideas: “ken” – meaning knowledge, an English word primarily used in Scotland, and “vue,” ref
- Johnson & Johnson Consumer Health Research Sheds Light on the Development of the Skin Microbiomehttps://practicaldermatology.com/news/johnson-johnson-consumer-health-research-sheds-light-on-the-development-of-the-skin-microbiome/2460428/New Johnson & Johnson Consumer Health research provides key insights into how the infant microbiome develops from birth to childhood. The findings, based on 10 years of data, were presented at the American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2020.
- Dr. Sandra Marchese Johnson, Yoseph Dalia Win Practical Dermatology®'s Best Paper of 2018 Awardhttps://practicaldermatology.com/news/dr-sandra-marchese-johnson-yoseph-dalia-win-practical-dermatologys-best-paper-of-2018-award/2459950/Fort Smith, Arkansas-based dermatologist Sandra Marchese Johnson MD, FAAD and Yoseph Dalia, BS took home Practical Dermatology®’s Best Paper of 2018 award for a Resident Resource Center submission that detailed the first reported case of facial rash following dupilumab
- EpigenCare Named as Johnson & Johnson Innovation Finalist in Skincare Challengehttps://practicaldermatology.com/news/epigencare-named-as-johnson-johnson-innovation-finalist-in-skincare-challenge/2457829/EpigenCare Inc., a personalized skincare startup company, is a finalist in Johnson & Johnson Innovation’s Digital Beauty Quickfire Challenge. The Challenge
- Johnson & Johnson Consumer to Acquire NeoStratahttps://practicaldermatology.com/news/johnson-johnson-consumer-to-to-acquire-neostrata/2458589/Johnson & Johnson Consumer, Inc. has entered into a definitive agreement to acquire NeoStrata Company, Inc. The acquisition will include NeoStrata's affiliates and parent company TriStrata, Incorporated, a privately-held compan
- Caliber Imaging & Diagnostics Names Daniel Koon to Director of Global Sales Supporthttps://practicaldermatology.com/news/20140314-caliber_imaging__diagnostics_names_daniel_koon_to_director_of_global_sales_support/2459316/Caliber Imaging & Diagnostics, formerly Lucid, Inc., named Daniel Koon to Director of Global Sales Support, effective immediately. Mr. Koon most recently served as Caliber I.D.'s Research Sales Manager. Mr. Koon has experience in international sales
- Phase 3 Icotrokinra Data Show Joint and Skin Improvements in Psoriatic Arthritishttps://practicaldermatology.com/news/phase-3-icotrokinra-data-show-joint-and-skin-improvements-in-psoriatic-arthritis/2488969/Once-daily oral icotrokinra (ICOTYDE; Johnson & Johnson) significantly improved joint disease activity compared with placebo in biologic-naive adults with active psoriatic arthritis (PsA), according to Phase 3 ICONIC-PsA 1 results presented at the American College of Rh
- 2-Year ICONIC-LEAD Data Show Sustained Psoriasis Responses With Oral Icotrokinrahttps://practicaldermatology.com/news/2-year-iconic-lead-data-show-sustained-psoriasis-responses-with-oral-icotrokinra/2488701/Two-year findings from the Phase 3 ICONIC-LEAD trial showed sustained skin clearance and itch improvement with icotrokinra (ICOTYDE; Johnson & Johnson) in adults and adolescents aged 12 years or older with moderate-to-severe plaque psoriasis, according to data presented at the 2026 Fall Clini